28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Twenty-nine articles met our inclusion criteria and were categorized into 3 groups as follows: (a) mobile versions of existing article or computerized neuropsychological tests; (b) new cognitive tests developed specifically for mobile platforms; and (c) the use of new types of data for cognitive assessment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study of brain networks by resting-state functional magnetic resonance imaging (rs-fMRI) is a promising method for identifying patients with dementia from healthy controls (HC). 2 key findings →
Participants: 89 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Rey-Osterrieth Complex Figure (ROCF) test is a commonly used neuropsychological assessment tool. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We urge the field to rethink metrics to account for diverse intra-individual experiences and trajectories of loneliness. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In South Korea, digital literacy education programs are expected to help its older population participate in online welfare services to increase their social support, self-esteem and well-being. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Elderly people affected by Mild Cognitive Impairment (MCI) usually report a perceived decline in cognitive functions that deeply impacts their quality of life. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The machine learning algorithm for NPTs has suggested potential use as a reference in differentiating cognitive impairment in the clinical setting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most common form of neurodegenerative dementia and its timely diagnosis remains a major challenge in biomarker discovery. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence (AI) is revolutionizing the field of medical imaging, offering unprecedented capabilities in data analysis, image interpretation, and decision support. 2 key findings →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper proposes a novel LLM-aided feature engineering approach that enhances interpretability by extracting clinically relevant features from the Oxford Textbook of Medicine. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Representations of White-racialized older adults were 5-fold higher than those of other races in both years. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCI prevalence was comparable across groups (7.5%-8.0%), but progression to dementia varied (9.4% Black vs. 11.4% Other). 5 key findings →
Participants: 83,180 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's Disease (AD) is a progressive neurodegenerative disease where biomarkers for disease based on pathophysiology may be able to provide objective measures for disease diagnosis and staging. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is the prodromal stage of Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropathologists assess vast brain areas to identify diverse and subtly-differentiated morphologies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Poor adherence to drug dosing schedule is responsible for ∼50% of hospitalization cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Subjects with Alzheimer's disease (AD) show loss of cognitive functions and change in behavioral and functional state affecting the quality of their daily life and that of their families and caregivers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identifying individuals at risk for progression of AD dementia could potentially help to personalize disease management to plan future care. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Utilizing the publicly available neuroimaging database enabled by Alzheimer's disease Neuroimaging Initiative (ADNI; http://adni.loni.usc.edu/ ), we have compared the performance of automated classification algorithms that differentiate AD vs. normal subjects using Positron Emission Tomography (PET) with fluorodeoxyglucose (FDG). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our aim is to develop a machine learning (ML) model that can predict dementia in a general patient population from multiple health care institutions one year and three years prior to the onset of the disease without any additional monitoring or screening. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia, a chronic and progressive cognitive declination of brain function caused by disease or impairment, is becoming more prevalent due to the aging population. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder, recognized as the most prevalent form of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
When analyzing multiple mobility metrics together, different combinations of mobility metrics are related to specific adverse health outcomes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →